Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer.

Cancers (Basel) · 2024 · PMC11083522 · PMID 38730700

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, subgroup analysis showed a trend toward better outcomes with paclitaxel plus trastuzumab in patients with longer interval between final dose of trastuzumab and paclitaxel plus trastuzumab.

also in 35,913 other papers

a favorable trendno p-value reported

QLQ-C30 and QLQ-STO22 scores showed a favorable trend in trastuzumab plus chemotherapy compared to chemotherapy alone.

also in 1,053 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.